Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 83162
1. Zmudka JA, Sérot JM, Dao S, Sorel C, Macaret AS, Balédent O: Specific Effects of Anti-Hypertensive Treatment in an Older Patient with Dementia. Open Neurol J; 2017;11:15-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific Effects of Anti-Hypertensive Treatment in an Older Patient with Dementia.
  • Dementia is one of the most common health problems in the world.
  • Alzheimer's disease (AD) is the most common form of dementia.
  • The relation between blood pressure (BP) and dementia has been the subject of numerous epidemiological studies, midlife HT is a risk factor for dementia and AD [3-7] but the association between HT and risk of dementia is lower in the older population [8].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Aging. 2000 Jan-Feb;21(1):49-55 [10794848.001]
  • [Cites] Lancet. 1996 Apr 27;347(9009):1141-5 [8609748.001]
  • [Cites] Can Fam Physician. 2013 Jan;59(1):19-21, 22-4 [23341648.001]
  • [Cites] Rev Med Interne. 2003 Oct;24 Suppl 3:283s-287s [14710445.001]
  • [Cites] Dement Geriatr Cogn Disord. 2016;41(5-6):314-23 [27398980.001]
  • [Cites] Am J Epidemiol. 2011 Mar 15;173(6):676-82 [21330339.001]
  • [Cites] J Hypertens. 2013 Sep;31(9):1731-68 [24029863.001]
  • [Cites] JAMA. 1963 Sep 21;185:914-9 [14044222.001]
  • [Cites] Hypertension. 2012 Apr;59(4):796-801 [22331381.001]
  • [Cites] J Nutr Health Aging. 2005;9(2):106-11 [15791354.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Oct;14(10):858-65 [10521885.001]
  • [Cites] J Alzheimers Dis. 2012;32(3):609-21 [22810098.001]
  • [Cites] Lancet Neurol. 2006 Sep;5(9):735-41 [16914401.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;31(2):152-7 [21335972.001]
  • [Cites] Ann Intern Med. 1990 Dec 15;113(12):941-8 [2240918.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;31(6):460-6 [21791923.001]
  • [Cites] Gerontologist. 1969 Autumn;9(3):179-86 [5349366.001]
  • [Cites] J Magn Reson Imaging. 2006 Nov;24(5):995-1004 [17024656.001]
  • [Cites] J Am Geriatr Soc. 2002 Aug;50(8):1431-8 [12165002.001]
  • [Cites] Dement Geriatr Cogn Disord. 2010;30(5):440-8 [21109737.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28567135.001).
  • [ISSN] 1874-205X
  • [Journal-full-title] The open neurology journal
  • [ISO-abbreviation] Open Neurol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Asprin / Cerebral blood flow / Dementia / Hypertension / MRI / Stroke
  •  go-up   go-down


2. Yang YW, Liu HH, Lin TH, Chuang HY, Hsieh T: Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS One; 2017;12(4):e0175335

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.
  • BACKGROUND: The effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with diabetes mellitus (DM) remain unknown.
  • We investigated the effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with DM.
  • We included 10,938 patients received one type of oxybutynin, solifenacin, or tolterodine, while 564,733 had not.
  • The dementia risk was estimated through multivariate Cox proportional hazard regression after adjustment for several confounding factors.
  • RESULTS: The dementia event rates were 3.9% in the oxybutynin group, 4.3% in the solifenacin group, 2.2% in the tolterodine group and 1.2% in the control group (P<0.001).
  • CONCLUSION: Our study indicates an association between taking oxybutynin, solifenacin and tolterodine and the subsequent diagnosis of dementia in DM patients.
  • The impact of these three drugs on risk of dementia in non-diabetic populations is warrant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urogynecol J. 2011 Aug;22(8):907-17 [21468739.001]
  • [Cites] Int J Clin Pract. 2010 Aug;64(9):1279-86 [20529135.001]
  • [Cites] Pharmacology. 2009;83(5):259-69 [19295256.001]
  • [Cites] Stroke. 2008 Oct;39(10):2744-8 [18583554.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1388-95 [18454794.001]
  • [Cites] J Urol. 2015 May;193(5):1572-80 [25623739.001]
  • [Cites] Pharmacol Ther. 2008 Feb;117(2):232-43 [18082893.001]
  • [Cites] Eur Urol. 2011 Mar;59(3):377-86 [21168951.001]
  • [Cites] JAMA. 2015 Jul 21;314(3):265-77 [26197187.001]
  • [Cites] BMJ. 2016 Mar 30;352:i1541 [27029385.001]
  • [Cites] Health Policy Plan. 2016 Feb;31(1):83-90 [25944704.001]
  • [Cites] PLoS One. 2014 Jan 29;9(1):e87095 [24489845.001]
  • [Cites] Eur Urol. 2014 Apr;65(4):755-65 [24275310.001]
  • [Cites] Endocr J. 2015;62(9):847-54 [26166691.001]
  • [Cites] JAMA Intern Med. 2015 Sep;175(9):1527-9 [26192815.001]
  • [Cites] Med Care. 2015 Feb;53(2):106-15 [25397966.001]
  • [Cites] Urology. 2011 Nov;78(5):1040-5 [21958505.001]
  • [Cites] BMJ. 2003 Apr 19;326(7394):841-4 [12702614.001]
  • [Cites] Eur Urol. 2013 Jul;64(1):74-81 [23332882.001]
  • [Cites] Arch Neurol. 2003 May;60(5):771-3 [12756144.001]
  • [Cites] J Formos Med Assoc. 2005 Mar;104(3):157-63 [15818428.001]
  • [Cites] Age Ageing. 2014 Sep;43(5):604-15 [25038833.001]
  • [Cites] Endocrine. 2016 Aug;53(2):350-63 [27160819.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Oct 15;22(8):739-47 [16197495.001]
  • (PMID = 28384267.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q: Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci; 2017;9:26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
  • <b>Objectives</b>: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD).
  • However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown.
  • <b>Methods</b>: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls.
  • The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski).
  • Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects.
  • <b>Conclusions</b>: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Aging Neurosci. 2015 Oct 27;7:203 [26578949.001]
  • [Cites] Curr Alzheimer Res. 2011 Mar;8(2):187-96 [21222606.001]
  • [Cites] J Alzheimers Dis. 2014;40(2):399-408 [24448787.001]
  • [Cites] Curr Alzheimer Res. 2014 May;11(4):340-8 [24720893.001]
  • [Cites] PLoS One. 2013;8(1):e55328 [23383156.001]
  • [Cites] Prog Neurobiol. 2013 Nov;110:2-28 [24036231.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1072-9 [18824671.001]
  • [Cites] Front Aging Neurosci. 2014 Jun 12;6:121 [24971061.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] Front Cell Neurosci. 2012 Dec 12;6:58 [23248582.001]
  • [Cites] Brain. 2011 Jan;134(Pt 1):258-77 [21186265.001]
  • [Cites] Front Cell Neurosci. 2014 Aug 14;8:231 [25177270.001]
  • [Cites] J Alzheimers Dis. 2010;21(2):471-8 [20555147.001]
  • [Cites] Cell Metab. 2014 Apr 1;19(4):574-91 [24508505.001]
  • [Cites] Neurology. 2014 Jul 1;83(1):40-7 [24907234.001]
  • [Cites] Front Mol Neurosci. 2012 Jul 06;5:79 [22783166.001]
  • [Cites] Front Aging Neurosci. 2016 Jul 28;8:179 [27516739.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Front Aging Neurosci. 2010 Jul 15;2:null [20725527.001]
  • [Cites] J Alzheimers Dis. 2010;22(3):985-91 [20858959.001]
  • [Cites] J Neurochem. 2012 Aug;122(4):752-63 [22679891.001]
  • [Cites] Neurobiol Dis. 2014 Dec;72 Pt A:22-36 [25131449.001]
  • [Cites] Aging Dis. 2013 Mar 07;4(2):57-64 [23696950.001]
  • [Cites] Mol Neurodegener. 2015 Dec 01;10:64 [26627638.001]
  • [Cites] Mol Neurobiol. 2014 Apr;49(2):1043-54 [24203677.001]
  • [Cites] J Alzheimers Dis. 2009;16(2):389-97 [19221428.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Front Biosci (Schol Ed). 2011 Jan 01;3:541-54 [21196395.001]
  • [Cites] Aging Dis. 2015 Oct 01;6(5):322-30 [26425387.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e62354 [23626805.001]
  • [Cites] Neurology. 2014 Nov 11;83(20):1812-8 [25305153.001]
  • [Cites] Autophagy. 2011 Jul;7(7):788-9 [21464620.001]
  • [Cites] Sci Rep. 2016 Aug 04;6:30741 [27489174.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):152-65 [15649706.001]
  • [Cites] Am J Pathol. 2010 Nov;177(5):2256-67 [20889561.001]
  • [Cites] Front Aging Neurosci. 2013 Sep 09;5:50 [24058343.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1440-2 [18026100.001]
  • [Cites] Neurobiol Aging. 2011 Aug;32(8):1435-42 [19773092.001]
  • [Cites] Brain. 2014 Dec;137(Pt 12):3300-18 [25270989.001]
  • [Cites] Prog Neurobiol. 2015 Jul 21;:null [26209472.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28223934.001).
  • [ISSN] 1663-4365
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Alzheimer’s disease / cystatin C / dementia / high-density lipoprotein / vascular dementia
  •  go-up   go-down


Advertisement
4. Dennis M, Shine L, John A, Marchant A, McGregor J, Lyons RA, Brophy S: Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study. Neurol Ther; 2017 Jun;6(1):57-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study.
  • INTRODUCTION: Over recent years there has been growing evidence of increased risk of mortality associated with antipsychotic use in older people with dementia.
  • The aim of this study was to assess adverse outcomes associated with the use of antipsychotics in older people living with dementia in Wales (UK).
  • METHODS: This was a retrospective study of a population-based dementia cohort using the Welsh Secure Anonymised Information Linkage databank.
  • RESULTS: A total of 10,339 people aged ≥65 years were identified with newly diagnosed dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2007 Jun 5;146(11):775-86 [17548409.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1048-52 [10744090.001]
  • [Cites] BMJ. 2014 Nov 03;349:g6420 [25368388.001]
  • [Cites] Am J Psychiatry. 2016 May 1;173(5):543-6 [27133416.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2015 May;24(5):468-77 [25410590.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;31(3):218-24 [21474930.001]
  • [Cites] Am J Geriatr Psychiatry. 2006 Mar;14 (3):191-210 [16505124.001]
  • [Cites] Am J Gastroenterol. 2013 Jul;108(7):1094-100 [23588238.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] J Psychopharmacol. 2009 Nov;23(8):909-14 [18635700.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476 [16437455.001]
  • [Cites] Emerg Themes Epidemiol. 2016 Oct 28;13:11 [27800007.001]
  • [Cites] J Biomed Inform. 2014 Aug;50:196-204 [24440148.001]
  • [Cites] BMJ. 2004 Jul 10;329(7457):75 [15194601.001]
  • [Cites] BMJ. 2007 Apr 21;334(7598):842-6 [17446616.001]
  • [Cites] JAMA. 2011 Sep 28;306(12):1359-69 [21954480.001]
  • [Cites] J Clin Psychopharmacol. 2013 Dec;33(6):753-8 [24052055.001]
  • [Cites] Am J Geriatr Psychiatry. 2009 May;17(5):417-27 [19390299.001]
  • [Cites] Arch Intern Med. 2008 May 26;168(10):1090-6 [18504337.001]
  • [Cites] J Clin Psychiatry. 2009 Oct;70(10):1340-7 [19906339.001]
  • [Cites] BMC Fam Pract. 2010 Jan 05;11:1 [20051110.001]
  • [Cites] Am J Geriatr Psychiatry. 2007 May;15(5):416-24 [17463191.001]
  • [Cites] Br J Psychiatry. 2014 Dec;205(6):436-42 [25452601.001]
  • [Cites] Nat Rev Neurol. 2009 May;5(5):245-55 [19488082.001]
  • [Cites] Nat Rev Neurosci. 2006 Jun;7(6):492-500 [16715057.001]
  • [Cites] CNS Drugs. 2002;16(11):765-76 [12383032.001]
  • [Cites] Am J Psychiatry. 2012 Jan;169(1):71-9 [22193526.001]
  • [Cites] Br J Psychiatry. 2012 Sep;201(3):221-6 [22790679.001]
  • [Cites] BMJ. 2012 Feb 23;344:e977 [22362541.001]
  • [Cites] BMJ. 2010 Sep 21;341:c4245 [20858909.001]
  • [Cites] Br J Gen Pract. 2010 Mar;60(572):e128-36 [20202356.001]
  • [Cites] Am J Psychiatry. 2013 Sep;170(9):1051-8 [23896958.001]
  • [Cites] Drug Saf. 2014 Jul;37(7):501-20 [24859163.001]
  • [Cites] BMC Health Serv Res. 2009 Sep 04;9:157 [19732426.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Dec;29(12):1249-54 [24633896.001]
  • [Cites] BMJ. 2015 Mar 02;350:h369 [25731881.001]
  • [Cites] Br J Psychiatry. 2014 Jul;205(1):44-51 [23929443.001]
  • [Cites] PLoS One. 2014 Aug 20;9(8):e105376 [25140533.001]
  • [Cites] BMC Med Inform Decis Mak. 2009 Jan 16;9:3 [19149883.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1426-33 [21764557.001]
  • (PMID = 28054240.001).
  • [ISSN] 2193-8253
  • [Journal-full-title] Neurology and therapy
  • [ISO-abbreviation] Neurol Ther
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MR/K006525/1; United Kingdom / Medical Research Council / / MRC/ MR/K023233/1
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; Antipsychotic medication / Dementia / Mortality / Older people
  •  go-up   go-down


5. O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, Mittler P, Passmore P, Ritchie C, Robinson L, Sampson EL, Taylor JP, Thomas A, Burns A: Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol; 2017 Feb;31(2):147-168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
  • The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs.
  • Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B).
  • Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A), memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B).
  • Drugs should not be stopped just because dementia severity increases (A).
  • Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A).
  • Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B).
  • Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A).
  • No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B).
  • Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B).
  • Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer's disease are in progress.
  • Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103749.001).
  • [ISSN] 1461-7285
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / DH/ HTA/15/62/02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alzheimer’s disease / Dementia / Lewy / frontotemporal / guidelines / management / treatment / vascular
  •  go-up   go-down


6. Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, Yeh CB: Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. J Am Geriatr Soc; 2017 Jul;65(7):1441-1447

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients.
  • OBJECTIVES: To determine the association between usages of proton pump inhibitors (PPIs) and subsequent risk of pneumonia in dementia patients.
  • PARTICIPANTS: The study cohort consisted of 786 dementia patients with new PPI usage and 786 matched dementia patients without PPI usage.
  • Cox model analysis also demonstrated that age (adjusted HR = 1.05; 95% CI = 1.03-1.06), male gender (adjusted HR = 1.57; 95% CI = 1.25-1.98), underlying cerebrovascular disease (adjusted HR = 1.30; 95% CI = 1.04-1.62), chronic pulmonary disease (adjusted HR = 1.39; 95% CI = 1.09-1.76), congestive heart failure (adjusted HR = 1.54; 95% CI = 1.11-2.13), diabetes mellitus (adjusted HR = 1.54; 95% CI = 1.22-1.95), and usage of antipsychotics (adjusted HR = 1.29; 95% CI = 1.03-1.61) were independent risk factors for pneumonia.
  • CONCLUSION: PPI usage in dementia patients is associated with an 89% increased risk of pneumonia.
  • [MeSH-major] Dementia / complications. Pneumonia / epidemiology. Proton Pump Inhibitors / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics Society.
  • (PMID = 28321840.001).
  • [ISSN] 1532-5415
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Keywords] NOTNLM ; dementia / pneumonia / population-based study / proton-pump inhibitors
  •  go-up   go-down


7. Paganini-Hill A, Greenia DE, Perry S, Sajjadi SA, Kawas CH, Corrada MM: Lower likelihood of falling at age 90+ is associated with daily exercise a quarter of a century earlier: The 90+ Study. Age Ageing; 2017 Mar 21;:1-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods: time spent in active physical activity was self-reported in 1980s; medical history, medication, assistive devices, residence type, and falls (outcome) was collected in 2000s.
  • In univariate analyses risk of falling at age 90+ was significantly related to medical history (heart disease, TIA/stroke, arthritis, vision disease, depression, dementia), medication use (hypnotics, anti-psychotics, anti-depressants), use of assistive devices (cane, walker, wheelchair), residence type (living with relatives, sheltered living), and source of information (self-report vs informant).
  • The odds ratio of falling was 0.65 (95% CI = 0.44-0.97) for 30-45 minutes/day and 0.64 (0.44-0.94) for 1+ hour/day adjusting for age, sex, medical history (stroke/TIA, vision disease, depression), use of assistive devices, and source of information.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28369185.001).
  • [ISSN] 1468-2834
  • [Journal-full-title] Age and ageing
  • [ISO-abbreviation] Age Ageing
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Falls / cohort / exercise / older people / oldest-old / risk factors
  •  go-up   go-down


8. Grimm MO, Michaelson D, Hartmann T: Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. J Lipid Res; 2017 May 20;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.
  • In the last decade it has become obvious that Alzheimer's disease (AD) is closely linked to changes in lipids or lipid metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017, The American Society for Biochemistry and Molecular Biology.
  • (PMID = 28528321.001).
  • [ISSN] 1539-7262
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alzheimer's disease / Amyloid beta / Apolipoproteins / Ceramides / DHA / Lipids / Nutrition / Sphingomyeline / multi-nutrients / n3 fatty acids
  •  go-up   go-down


9. Bain KT, Schwartz EJ, Chan-Ting R: Reducing Off-Label Antipsychotic Use in Older Community-Dwelling Adults With Dementia: A Narrative Review. J Am Osteopath Assoc; 2017 Jul 01;117(7):441-450

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing Off-Label Antipsychotic Use in Older Community-Dwelling Adults With Dementia: A Narrative Review.
  • The off-label use of antipsychotics for the management of behavioral and psychologic symptoms of dementia (BPSD) in older adults (age ≥65 years) is common, despite evidence of modest benefits and serious risks.
  • Although national initiatives aimed at reducing antipsychotic use among older adults with BPSD in nursing homes have been successful, similar initiatives are lacking for community-dwelling adults with dementia.
  • Physicians should be knowledgeable of this issue and understand the alternatives to antipsychotics, as well as how to reduce antipsychotic use in patients with dementia who are already taking antipsychotics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28662557.001).
  • [ISSN] 1945-1997
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Cheung CY, Ikram MK, Chen C, Wong TY: Imaging retina to study dementia and stroke. Prog Retin Eye Res; 2017 Mar;57:89-107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging retina to study dementia and stroke.
  • With increase in life expectancy, the number of persons suffering from common age-related brain diseases, including neurodegenerative (e.g., dementia) and cerebrovascular (e.g., stroke) disease is expected to rise substantially.
  • As current neuro-imaging modalities such as magnetic resonance imaging may not be able to detect subtle subclinical changes (resolution <100-500 μm) in dementia and stroke, there is an urgent need for other complementary techniques to probe the pathophysiology of these diseases.
  • In this review, we present an overview of the current literature on the application of retinal imaging in the study of dementia and stroke.
  • We discuss clinical implications of these studies, novel state-of-the-art retinal imaging techniques and future directions aimed at evaluating whether retinal imaging can be an additional investigation tool in the study of dementia and stroke.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28057562.001).
  • [ISSN] 1873-1635
  • [Journal-full-title] Progress in retinal and eye research
  • [ISO-abbreviation] Prog Retin Eye Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alzheimer's disease / Cerebrovascular disease / Dementia / Retinal ganglion cell / Retinal imaging / Retinal microvasculature / Stroke
  •  go-up   go-down






Advertisement